Disclosures for "Long-term Tolerability and Efficacy of Adjunctive Brivaracetam in Pediatric Patients with Primary Generalized Seizures: Subgroup Analysis of an Open-label, Follow-up Trial"
-
Dr. Lagae has nothing to disclose.
-
The institution of Mrs. de la Loge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for UCB.
-
Dr. Elmoufti has nothing to disclose.
-
Dr. Elshoff has nothing to disclose.
-
Dr. Moseley has received personal compensation for serving as an employee of UCB. Dr. Moseley has received personal compensation for serving as an employee of Neurocrine Biosciences Inc. Dr. Moseley has stock in UCB. Dr. Moseley has stock in Neurocrine Biosciences.
-
Dr. Pucylowski has received personal compensation for serving as an employee of UCB, Inc.. Dr. Pucylowski has stock in UCB, Inc..
-
Dr. Bourikas has nothing to disclose.